Traders Buy High Volume of Call Options on Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics, Inc. (NASDAQ:VKTXGet Free Report) was the recipient of unusually large options trading on Monday. Stock traders purchased 16,078 call options on the stock. This represents an increase of 22% compared to the typical volume of 13,155 call options.

Analyst Ratings Changes

VKTX has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $90.00 price objective on shares of Viking Therapeutics in a research note on Friday, March 15th. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a report on Friday, February 23rd. Raymond James boosted their price objective on Viking Therapeutics from $37.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, February 27th. StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a report on Friday, February 9th. Finally, Oppenheimer lifted their price objective on shares of Viking Therapeutics from $46.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Viking Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $96.67.

Read Our Latest Analysis on Viking Therapeutics

Viking Therapeutics Stock Performance

NASDAQ VKTX opened at $65.18 on Wednesday. The stock has a market cap of $6.55 billion, a price-to-earnings ratio of -70.85 and a beta of 1.06. The business has a 50 day simple moving average of $42.64 and a 200 day simple moving average of $23.89. Viking Therapeutics has a 52-week low of $8.28 and a 52-week high of $99.41.

Viking Therapeutics (NASDAQ:VKTXGet Free Report) last released its earnings results on Wednesday, February 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.25). During the same quarter in the prior year, the company posted ($0.26) earnings per share. On average, analysts predict that Viking Therapeutics will post -1.1 EPS for the current year.

Insiders Place Their Bets

In other Viking Therapeutics news, Director Sarah Kathryn Rouan sold 30,000 shares of Viking Therapeutics stock in a transaction on Friday, January 19th. The shares were sold at an average price of $23.05, for a total transaction of $691,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Greg Zante sold 15,000 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $17.90, for a total value of $268,500.00. Following the sale, the chief financial officer now owns 180,730 shares of the company’s stock, valued at $3,235,067. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Sarah Kathryn Rouan sold 30,000 shares of the business’s stock in a transaction on Friday, January 19th. The shares were sold at an average price of $23.05, for a total transaction of $691,500.00. The disclosure for this sale can be found here. Insiders sold 374,079 shares of company stock worth $9,729,653 over the last three months. 4.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Viking Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Retirement Group LLC boosted its position in shares of Viking Therapeutics by 75.0% during the 2nd quarter. Retirement Group LLC now owns 2,100 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 900 shares in the last quarter. Cetera Advisor Networks LLC bought a new position in Viking Therapeutics in the 2nd quarter valued at about $36,000. Engineers Gate Manager LP purchased a new stake in shares of Viking Therapeutics in the first quarter valued at about $37,000. Wetzel Investment Advisors Inc. bought a new position in shares of Viking Therapeutics in the fourth quarter valued at approximately $37,000. Finally, US Bancorp DE increased its position in shares of Viking Therapeutics by 66.5% during the 4th quarter. US Bancorp DE now owns 2,346 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 937 shares during the last quarter. 78.13% of the stock is owned by institutional investors and hedge funds.

Viking Therapeutics Company Profile

(Get Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Featured Articles

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.